Bank of India Large & Mid Cap Fund
The scheme aims at income and long-term capital appreciation by investing through a diversified portfolio of predominantly large cap and mid cap equity and equity-related securities including equity derivatives.
Growthvine rating: 2/5 — ranked #28 of 39 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹93.89 (as of 2026-08-21) |
|---|
| AUM | ₹491 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nitin Gosar |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| 5-year annualised return | 12.04% |
|---|
| Sharpe ratio | 0.53 |
|---|
| Standard deviation | 15.75% |
|---|
| Max drawdown | -39.51% |
|---|
| Alpha | 1.34 |
|---|
| Beta | 1.02 |
|---|
Over 5 years, captured 93.7% of NIFTY LargeMidcap 250's upside and 101.1% of its downside.
Market cap allocation
| Large cap | 44.9% |
|---|
| Mid cap | 39.0% |
|---|
| Small cap | 16.0% |
|---|
Concentration
| Top 5 holdings | 26.5% |
|---|
| Top 10 holdings | 42.5% |
|---|
| Total holdings | 50 |
|---|
| Index overlap | 26.6% |
|---|
| Active share | 73.4% |
|---|
Top holdings
- HDFC Bank Ltd. — 8.1%
- Reliance Industries Ltd — 6.3%
- Dixon Technologies (India) Limited — 4.3%
- TREPS — 4.2%
- FSN E-Commerce Ventures Limited — 4.2%
- Kotak Mahindra Bank Ltd. — 3.5%
- Larsen & Toubro Limited — 3.5%
- Aurobindo Pharma Ltd. — 3.5%
- State Bank Of India — 3.3%
- PETRONET LNG LTD. — 2.9%
Top sectors
- Banking & Financial — 18.4%
- Pharma & Biotech — 11.7%
- Retail — 7.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 2.1% | Q2 | #17 of 38 |
| 2025 | 6.8% | Q2 | #12 of 34 |
| 2024 | 16.6% | Q4 (Bottom) | #23 of 29 |
| 2023 | 29.3% | Q3 | #16 of 28 |
| 2022 | 1.9% | Q2 | #14 of 28 |